Friday, August 21, 2026
GlobeNewsInfo Logo
Home / Health & Medical / VitriVax secures $87 million Series C financing to advance single-dose Lyme disease vaccine into clinical trials

VitriVax secures $87 million Series C financing to advance single-dose Lyme disease vaccine into clinical trials

Published on
VitriVax secures $87 million Series C financing to advance single-dose Lyme disease vaccine into clinical trials
Image used for illustrative purposes only. GlobeNewsInfo / Visuals

VitriVax has closed an $87 million Series C financing round to advance its single-dose Lyme disease vaccine candidate into first-in-human clinical trials. Backed by major institutional investors, the capital will also expand the company’s proprietary ALTA platform pipeline, addressing critical gaps in global vaccine accessibility and immunogenicity.

UNITED STATES OF AMERICA —VitriVax has successfully closed an $87 million Series C financing round to propel its lead Lyme disease vaccine candidate into initial human clinical trials. The investment consortium was co-led by F-Prime, NEA, RA Capital Management, and Sanofi Ventures, with additional participation from Eli Lilly and Company. This capital injection is designated to accelerate first-in-human data generation and broaden the organization’s pipeline of proprietary immunization programs.

This development addresses a persistent clinical and commercial vulnerability in current vector-borne disease prevention. Existing late-stage Lyme disease vaccines under development require complex multi-dose primary series and seasonal boosters, a regimen that historically sees up to half of patients discontinuing treatment prematurely. By engineering a single-dose alternative, the company aims to drastically improve patient compliance and real-world efficacy rates across highly endemic regions in North America and Europe.

The broader biotechnology and public health sectors stand to benefit from the underlying Atomic Layering Thermostable Antigen and Adjuvant platform. This formulation technology is engineered to enhance immunogenicity while reducing antigen and adjuvant requirements, thereby lowering manufacturing costs. Furthermore, the platform supports messenger RNA delivery without relying on lipid nanoparticles and minimizes cold-chain dependencies, which is critical for expanding vaccine accessibility in resource-constrained global markets.

Strategically, this funding milestone transitions the entity from a pure technology platform into a fully integrated vaccine development organization. Building upon a previous $17.25 million Series B round and non-dilutive grants from the Gates Foundation, the Coalition for Epidemic Preparedness Innovations, and the United States Department of Defense, the company is now positioned to advance multiple indications. These include ongoing partner-funded initiatives targeting rabies, melioidosis, polio, and HIV, signaling strong institutional confidence in next-generation vaccine economics and global health preparedness.

VitriVax is a Boulder, Colorado-based biotechnology firm specializing in advanced vaccine development and formulation technologies. The organization focuses on creating thermostable, single-dose immunizations designed to overcome traditional logistical and immunological barriers in global healthcare delivery.

About GlobeNewsInfo

GlobeNewsInfo is a business news platform providing latest updates on global business developments, projects, and contract opportunities across diverse sectors and regions. The platform is designed to serve as a trusted source of information for companies, investors, and professionals worldwide.

More on Health & Medical

Latest Business News

Share this Article

Just In
2 hours ago NIB commits EUR 70 million ten-year facility to Nefco for Ukrainian municipal green projects 2 hours ago EIB backs Théa with EUR 150 million loan to expand European eye care R&D and manufacturing 2 hours ago UAE Ministry of Finance launches bids for penetration testing and security vulnerability assessment project 2 hours ago Eimskip expands Reyðarfjörður cargo capacity with electric mobile harbor crane